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Toulouse, Franceb; Laboratoire de Virologie Hôpital Pitié Salpêtrière, Paris, France, and INSERM U943, Université Pierre et Marie Curie, Paris, Francec; Laboratoire de
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There is evidence that HIV-1 evolution under maraviroc (MVC) pressure can lead to the selection of either X4-tropic variants
and/or R5-tropic, MVC-resistant isolates. However, the viral dynamics of HIV-1 variants in patients with virological failure (VF)
on MVC-containing regimens remain poorly studied. Here, we investigated the V3 loop evolution of HIV-1 on MVC in relation
to coreceptor usage and the nature of HIV-1 quasispecies before MVC therapy using bulk population sequences and ultradeep
sequencing. The majority of patients had no detectable minority X4 variant at baseline. The evolution of tropism was followed
up until VF and showed three possibilities for viral evolution in these patients: emergence of preexisting X4 variants, de novo
selection of R5 variants presenting V3 loop mutations, or replication of R5 variants without selection of known mutations.
Human immunodeficiency virus type 1 (HIV-1) infection in-volves an interaction between the viral envelope protein and
the CD4 molecule. The V3 loop is then exposed and engages the
coreceptor (CCR5 or CXCR4), which mediates membrane fusion.
In the early stages of HIV-1 infection, CCR5 usage is predomi-
nant. The receptor switch to CXCR4 occurs often in infected in-
dividuals (around 40%) and is associated with faster disease pro-
gression (1). CCR5 inhibitors inhibit HIV-1 entry by blocking the
CCR5 coreceptor. The binding of these small molecules to a cavity
of the membrane domain of CCR5 stabilizes the coreceptor in a
conformation which can no longer be recognized by the HIV-1
gp120 (2, 3). Maraviroc (MVC) is the first CCR5 inhibitor used for
the treatment of CCR5-tropic HIV-1 infection (4). Two mecha-
nisms of escape to MVC have been so far described in vitro and in
vivo (5, 6). The first mechanism includes the selection of minority
variants using the CXCR4 coreceptor; the second possibility is the
emergence of CCR5-tropic resistant isolates which can still use the
CCR5 coreceptor in the presence of the inhibitor. However, few
studies have described the relative importance of the two mecha-
nisms in MVC-treated patients (7, 8).
In this study, we described that the coreceptor switch occurred
in only 30% of the patients, and we also characterized the geno-
typic evolution of HIV-1 isolates in patients with virological fail-
ure on MVC-based regimens.
MATERIALS AND METHODS
Study population. Included patients were screened for the maraviroc ex-
panded-access protocol (MVC EAP) in France between January 2007 and
August 2008 and received MVC associated with an optimized background
therapy if the result of the phenotypic assay for coreceptor use determi-
nation was CCR5, using a previously validated assay (Trofile; Monogram
Biosciences) (9). For some patients, a modified version with an optimized
sensitivity of the assay was performed (ESTA) once it became available
(10). Inclusion criteria for the MVC EAP were HIV-1 infection, age of
18 years, with previous antiretroviral therapy and virological failure
with plasma HIV-1 RNA of 1,000 copies/ml. Patients from 18 centers in
France were included in the virological GenoTropism study (11). So-
ciodemographic data, clinical data, and treatment histories were collected
for all enrolled patients at the screening date. MVC-treated patients were
followed up at baseline (M0) and at months 1, 3, and 6 on MVC-contain-
ing regimens (M1, M3, and M6). The patients had signed the MVC EAP
informed consent form and were specifically informed about their partic-
ipation in the GenoTropism study. The study was approved by the Comité
Consultatif de Traitement de l’Information dans la Recherche Scienti-
fique et Médicale and the Commission Nationale Informatique et Liber-
tés. Only patients treated by MVC and with virological failure (VF; de-
fined as plasma viral load [VL] above 50 copies/ml at month 3 or month 6)
and available plasma samples at baseline and follow-up were studied here.
Virological methods. (i) Population sequencing. The sequence
analysis comprising the complete V3 loop sequence was performed
from plasma sampled at baseline MVC and at the time of follow-up
with VL of 50 copies/ml. PCR primers and conditions and sequenc-
ing primers are described in the ANRS consensus techniques (http:
//www.hivfrenchresistance.org). PCR products were sequenced as de-
scribed in the previous publication (11).
(ii) Ultradeep sequencing. Env C2V3 quasispecies were determined at
M0 by 454 ultradeep sequencing (UDS; Roche). A 415-nucleotide frag-
ment encompassing the V3 env region was generated by nested reverse
transcription (RT)-PCR. The nested PCR was performed with the Expand
high-fidelity Plus PCR system (Roche Diagnostics), with the following
conditions: 1 cycle of 94°C for 2 min; 35 cycles of 94°C for 30 s, 60°C for 30
s, and 72°C for 3 min; followed by a final extension at 72°C for 7 min. The
amplified PCR products were purified by using Agencourt Ampure PCR
purification beads (Beckman Coulter, Brea, CA) and quantified with the
Quant-iT Picogreen double-stranded DNA (dsDNA) assay kit (Invitro-
gen) on a LightCycler 480 (Roche). Pooled PCR products were clonally
amplified on capture beads in water-in-oil emulsion microreactors, and
pyrosequencing was performed by using PicoTiterPlate, following the
standard approach for PCR amplicon sequencing. A total of 500,000 en-
riched DNA beads were deposited in the wells of a full GS Junior Titanium
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1 M0 DRV RAL ENF 5.8 20 R5 2.5 R5
M1 5.5 12 X4 ND R5X4
M6 5.6 39 X4 ND R5X4
2 M0 ETR RAL 5.2 336 R5 0 R5
M3 2.8 376 R5 ND ND
3 M0 3TC ETR DRV RAL 5.2 3 R5 0 R5
M3 4.4 6 R5 ND ND
M6 4.6 8 R5 ND ND
4 M0 TDF FTC RAL 5.4 130 R5 0 R5
M6 2.1 342 R5 ND ND
5 M0 AZT 3TC ABC ETR DRV RAL 5.2 15 R5 0.74 ND
M1 5 70 X4 ND X4
M3 4.5 93 X4 ND ND
M6 3.2 193 X4 ND ND
6 M0 DRV RAL 4.7 607 R5 0 R5
M1 5 374 R5 ND R5
M3 3 460 R5 ND R5
M6 2.5 642 R5 ND ND
7 M0 DRV RAL 5.2 607 R5 ND ND
M3 2.9 460 X4 ND ND
8 M0 TDF FTC DRV 4.5 45 R5 0 R5
M6 3 124 R5 ND R5
9 M0 fAPV RAL ENF 4.5 131 R5 0 R5
M3 3.3 132 X4 ND X4
M9 3.6 206 R5 ND ND
10 M0 TDF FTC DRV 5.6 27 R5 1.3 R5
M6 5.1 58 R5 ND R5
11 M0 ABC 3TC DRV ENF 4.6 316 R5 0.3 R5
M6 2.2 400 R5 ND ND
12 M0 3TC ABC TDF ETR DRV ATV 5.2 82 R5 0 R5
M3 3.5 383 R5 ND R5
13 M0 3TC ETR DRV ATV RAL 2.4 276 R5 76.1 R5
M3 2.3 457 R5 ND R5
14 M0 DRV RAL 2.1 541 R5 ND ND
M3 2.4 390 R5 ND ND
M6 2.7 243 R5 ND ND
15 M0 RAL 3 323 R5 0 R5
M6 2.1 360 R5 ND ND
16 M0 DRV 3.9 434 R5 0 R5
M6 5.1 642 R5 ND R5
17 M0 TDF FTC TPV RAL 5.5 131 X4 100 R5X4
M1 4.3 121 X4 ND ND
M3 4.5 160 X4 ND ND
a OBT, optimized background therapy; TTT, Toulouse tropism test; M0, follow-up at baseline; M1, M3, and M6, follow-up at months 1, 3, and 6 on MVC-containing regimens;
DRV, darunavir; RAL, raltegravir; ENF, enfuvirtide; ETR, etravirine; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine; AZT, zidovudine; ABC, abacavir; fAPV, fosamprenavir;
ATV, atazanavir; R5, CCR5; X4, CXCR4; ND, no data.
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PicoTiterPlate device and pyrosequenced in both forward and reverse
directions. The 200 nucleotide cycles were performed in a 10-h sequenc-
ing run. For each sample, a fasta file containing nucleotide sequence data
was obtained.
(iii) Phylogenetic analysis. Phylogenetic analyses were performed on
V3 sequences, including both 454 sequences and population sequencing
data, using the neighbor-joining method on Clustal W2 software and trees
designed with the iTOL website (12).
(iv) Genotypic and phenotypic prediction of coreceptor usage. Co-
receptor usage was predicted from V3 sequences using the Geno2pheno
algorithm (http://coreceptor.bioinf.mpi-inf.mpg.de/) by selecting a false-
positive rate (FPR) at 10% for sequences issued from population sequenc-
ing or a false-positive rate at 5.75% or 3.5% (13, 14) for the calculation of
the X4 virus frequency for the 454 sequences.
Coreceptor usage was also determined at M0 and at follow-up by
phenotypic analysis using a recombinant assay (Toulouse tropism test)
(15).
RESULTS
Patients’characteristics. Seventeen patients were included in this
study. Patient characteristics are detailed in Table 1. At baseline,
before maraviroc-containing therapy, the median plasma HIV-1
RNA was 5.2 log10 copies/ml (range, 2.1 to 5.8), and at VF (M6),
the median plasma HIV-1 RNA was 3 log10 copies/ml (range, 1.6
to 5.6). The median CD4 cell count was 131 cells/mm3 (range, 3
to 607) at baseline MVC and 320 cells/mm3 (range, 8 to 642) at
M6. The antiretroviral drugs coadministered with MVC included
nucleoside or nucleotide RT inhibitors for 9 patients, ritonavir-
boosted protease inhibitors in 12 patients, a nonnucleoside RT
inhibitor (etravirine) in 4 patients, an integrase inhibitor (ralte-
gravir) in 11 patients, and a fusion inhibitor (enfuvirtide) in 3
patients.
Baseline MVC HIV-1 coreceptor usage. The inferred HIV-1
coreceptor usage from genotype was determined at baseline MVC
from bulk HIV-1 plasma RNA. The genotypic analysis of the V3
loop, using the Geno2pheno (FPR, 10%) algorithm, showed an R5
tropism for all patients but one (Table 1). HIV-1 tropism using a
phenotypic test (15) was determined at baseline MVC for 14 pa-
tients. These results were concordant with the genotypic determi-
nation, with R5 tropism for 13 patients and an R5X4 result for the
patient with X4 genotypic tropism at baseline (and determined as
R5 by Trofile assay).
The percentage of X4 variants could be determined by ul-
tradeep sequencing of the V3 loop in 15 patients at baseline. The
median number of analyzed sequences for each patient was 3,240
(range, 1,034 to 7,585). Out of 14 patients with R5 tropism from
bulk population analysis, 9 had 0% of X4 isolates with UDS; 4
patients had minority X4 variants, ranging between 0.3% to 2.5%
of the global population; and one patient had 76.1% of X4 vari-
ants. The patient with the X4 bulk population tropism was shown
to have 100% of X4 variants by UDS.
Evolution of coreceptor usage at virological failure. Both
population sequencing and phenotypic analysis showed a switch
from R5 isolates at baseline to X4 isolates at VF in 4 patients, a
stable R5 coreceptor use in 12 patients, and a stable X4 tropism in
one patient. Of note, one patient (patient 9) with a switch from R5
isolate at baseline to X4 isolate at M3 reversed to R5 tropism at M6.
Three (patients 1, 5, and 17) of 6 patients with minority X4 vari-
ants and 1/9 patient (patient 9) with 0% of X4 variants at baseline
harbored X4 viruses at virological failure (Fisher’s exact test, P 
0.23).
Evolution of V3 quasispecies on MVC. Phylogenetic trees
could be constructed for 15 patients, with each tree including V3
loop sequences obtained from population sequencing at baseline
MVC and at virological failure and sequences obtained by ul-
tradeep sequencing at baseline MVC. This enabled us to define the
most proximal UDS sequences to bulk sequences at baseline and
at failure. Four examples of phylogenetic trees are shown in Fig. 1,
showing different dynamics: a switch from the R5 isolate to a
stable X4 population for patient 5, an R5 population for patient 6
with a low sequence variability, a selection of the X4 variant fol-
lowed by a return to the baseline R5 population in patient 9, and
an evolving X4 population in patient 17. In order to define specific
mutations appearing at virological failure on MVC, we aligned the
V3 loop amino acid sequences obtained at baseline and at failure
and the proximal baseline UDS sequences for each patient (Fig. 2).
For the three patients (1, 5, and 9) with selection of X4 variants,
multiple mutations were selected at failure, including changes at
critical amino acids 11 and 25. For patient 1 and 5, 2.5% and
0.74% of X4 variants were detected at baseline, including most
proximal sequences to VF. For patient 9, no X4 minority variant
was detected at baseline.
In a majority of patients, R5 sequences were found at virolog-
ical failure. In 8 patients (patients 2, 4, 6, 8, 11, 12, 13, 16), a stable
genotype was found over time. In three patients, the presence of
multiple mutations was found in the V3 loop: mutations 13S, 22T,
and 24A for patient 3; mutations 13P and 25Q for patient 10; and
mutations 13S, 25G, 29D, and 34Y for patient 15. The correspond-
ing mutations were not found in the most proximal UDS se-
quences at M0, suggesting that these mutations could have been
selected later during MVC exposure.
DISCUSSION
In this study, we could characterize the evolution of HIV-1 quasi-
species in patients enrolled in the GenoTropism study and having
FIG 1 V3 quasispecies at baseline and at failure. Phylogenetic analysis, based
on the neighbor-joining method, of the HIV-1 V3 region using 454 sequences
at M0 and population sequences at times indicated for 4 patients. Correspond-
ing tropisms are indicated between brackets. Only consensus sequences are
represented for patient 6.
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VF on MVC-containing regimens. The risk of VF has been shown
to be independently associated with an X4 tropism at baseline
MVC (determined from V3 sequences and the Geno2pheno algo-
rithm), with a lower weighed genotypic sensitivity score (GSS), a
higher baseline viral load, and a lower nadir of CD4 cells (11).
Here, we focused on the evolution of coreceptor usage and the
genetic evolution of V3 sequences in 17 patients with VF. Both
genotypic and phenotypic tests showed that in all patients but one,
the majority viral population used the CCR5 coreceptor at base-
line. The diversity of env quasispecies at baseline MVC was studied
FIG 2 Virological evolution of the V3 region in the patients failing on MVC. The number of 454 sequences used for the analysis is determined in the first column.
Prox M indicated the 454 sequence found to be the most closely related to the bulk population sequence at the studied time. For patient 10, no proximal sequence
was identified to M6 bulk sequence. No 454 data were available for patients 7 and 14. Columns for amino acids at positions 11 and 25 are in gray. Black arrows
indicate positions of known mutations. Black circles indicate positions of mutations observed in this study.
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by UDS. In a majority of patients (9/14) with R5 tropism from
bulk population analysis, no minority X4 variant could be found.
However, 4 patients had minority X4 variants, and one was found
to have majority X4 variants by UDS. The evolution of tropism
could be followed up at VF, showing a switch from R5 isolates to
X4 isolates in 4 patients, a stable R5 tropism in 12 patients, and a
stable X4 tropism in one patient.
To investigate the dynamics of evolution of the env V3 loop
between baseline MVC and VF, we constructed phylogenetic trees
comprising all env baseline quasispecies and the bulk variants se-
lected at VF. The switch from R5 to X4 tropism occurred in only
30% of the patients. In this case, multiple V3 mutations were
selected at VF, including typical changes at amino acids 11 and 25
associated with X4 tropism. In 2/3 patients, preexisting X4 vari-
ants carrying all or most of these mutations were detected as mi-
nority variants at baseline, in agreement with a previous report
showing that minority X4 variants could be selected by MVC (8).
In patients with R5 tropism at VF, the picture was more complex.
A majority of patients showed no evolution of V3 sequence be-
tween baseline MVC and VF. At least three mechanisms could be
involved in these patients: (i) a nonoptimal adherence to antiret-
roviral therapy (ART) could have led to VF; however, most pa-
tients showed a decrease in plasma HIV-1 RNA between M0 and
VF, which is not in favor of this possibility; (ii) a suboptimal effi-
cacy of the whole ART regimen, despite partial efficacy due to
MVC; (iii) resistance to MVC or CXCR4 usage could be encoded
by genetic changes occurring out of the V3 loop, since changes in
gp41 have been previously shown to influence coreceptor tropism
(16, 17) and mutations in the gp120 V4 loop have been shown to
modulate resistance to MVC (18). As an additional means of re-
sistance, we could not exclude that MVC-resistant viruses utilized
the drug-bound form of the receptors as previously described in
vitro (5, 6, 19).
Three patients presented R5 isolates at VF with the selection of
multiple mutations in the V3 loop. Because these mutations were
absent from baseline sequences, they are likely to correspond to de
novo viral evolution to use MVC-bound CCR5, as previously sug-
gested (18). In the latter report, mutations P/T308H, T320H, and
I322V in HXB2 gp120 (corresponding to amino acids 13, 23, and
25 in the V3 loop) were described in clinical isolates from patients
with VF on MVC and were shown to code for resistance to MVC.
In a previous report, mutations A316T, A319S, and I323V (V3
loop positions 19, 20, and 26), in vitro selected in the presence of
MVC, were also shown to promote MVC resistance. Other pat-
terns have been described in patients with VF in the MOTIVATE
trial (20, 21) but without full molecular characterization. In our
three patients, changes at position 13 were selected or present at
baseline and VF, suggesting that this position may be critical for
resistance to MVC. However, more data will be necessary to es-
tablish correlations between genotype and phenotype (and/or VF)
for resistance to MVC, since mutation patterns seem to vary im-
portantly among patients, suggesting a role of env variability back-
ground for establishment of resistance.
These V3 loop mutations should be further investigated to un-
derstand how they mediate MVC antiviral effects. We cannot also
exclude a relationship between the background antiviral regimens
and the likelihood of development of resistance against MVC. The
numbers of patients were, however, too small to assess a signifi-
cant relationship between the GSS and the different patterns ob-
served at VF.
In conclusion, our study confirms two possibilities for viral
evolution in patients with VF on MVC: emergence of preexisting
X4 variants or de novo selection of R5 variants presenting V3 loop
mutations. Besides these two patterns, the replication of R5 vari-
ants without selection of mutations warrants further pharmaco-
kinetical and/or virological studies outside the V3 loop.
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